Blocking P2X7 receptor ameliorates oxidized LDL-mediated podocyte apoptosis

Area of Science:

• Nephrology
• Cell Biology
• Molecular Biology

Background:

• Podocyte injury is a key factor in kidney disease progression.
• Oxidized low-density lipoprotein (oxLDL) is implicated in podocyte damage.
• The P2X7 receptor (P2X7R) role in podocyte apoptosis requires further elucidation.

Purpose of the Study:

• To determine if oxLDL activates P2X7R in human podocytes.
• To investigate if P2X7R activation induces podocyte apoptosis.
• To explore the molecular mechanisms underlying oxLDL-induced podocyte apoptosis.

Main Methods:

• Human podocytes were treated with oxLDL and/or the P2X7R antagonist A438079.
• Cellular apoptosis and reactive oxygen species (ROS) were quantified via flow cytometry.
• Protein expression of P2X7R, Bax, and Caspase-3 was analyzed using Western blot and immunofluorescence.

Main Results:

• oxLDL significantly increased P2X7R, ROS, Bax, and Caspase-3 expression, alongside lipid accumulation and apoptosis in podocytes.
• Co-treatment with A438079 markedly reduced oxLDL-induced ROS, Bax, and Caspase-3 levels.
• A438079 administration also decreased lipid accumulation and podocyte apoptosis.

Conclusions:

• P2X7R activation is implicated in oxLDL-induced human podocyte apoptosis.
• The P2X7R pathway, involving ROS, Bax, and Caspase-3, mediates oxLDL-induced podocyte injury.
• P2X7R antagonism offers a potential therapeutic strategy against oxLDL-related podocyte damage.